Literature DB >> 6117727

D-TRP5-analogue of luteinising hormone releasing hormone in combination with cyproterone acetate to treat precocious puberty.

Z Laron, R Kauli, Z B Zeev, A M Comaru-Schally, A V Schally.   

Abstract

A 6-year-old girl with central (true) precocious puberty was successfully treated with a combination of the luteinising hormone releasing hormone analogue (D-Trp6)-LH-RH and cyproterone acetate. This treatment led to an almost complete arrest of gonadotrophin and oestrogen secretion, induced regression of pubertal signs, and markedly slowed bone maturation. It is suggested that the paradoxical refractoriness of the gonadotrophic and gonadal cells induced by long-term treatment with LH-RH agonists can be exploited in the treatment of precocious puberty.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6117727     DOI： 10.1016/s0140-6736(81)91155-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  9 in total

1.  The effect of cyproterone acetate on the growth of children with central precocious puberty.

Authors:  R Stanhope; K F Huen; F Buzi; M A Preece; D B Grant
Journal:  Eur J Pediatr       Date:  1987-09       Impact factor: 3.183

2.  Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations.

Authors:  M Mason-Garcia; S Vigh; A M Comaru-Schally; T W Redding; A Somogyvari-Vigh; J Horvath; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

3.  Clinical and endocrinologic study of precocious puberty in girls.

Authors:  A Ortner; J Glatzl; E Karpellus
Journal:  Arch Gynecol       Date:  1987

Review 4.  Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.

Authors:  B J Furr; J R Woodburn
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

5.  The effect of treatment with an LH-RH agonist (Buserelin) on gonadal activity growth and bone maturation in children with central precocious puberty.

Authors:  S L Drop; R J Odink; C Rouwé; B J Otten; M W Van Maarschalkerweerd; M Gons; A Bot; M Meradji; F H de Jong; F M Slijper
Journal:  Eur J Pediatr       Date:  1987-05       Impact factor: 3.183

6.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

Authors:  G Tolis; D Ackman; A Stellos; A Mehta; F Labrie; A T Fazekas; A M Comaru-Schally; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

7.  Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.

Authors:  T W Redding; A V Schally; T R Tice; W E Meyers
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

Review 8.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

9.  Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.

Authors:  J H Waxman; J A Wass; W F Hendry; H N Whitfield; G M Besser; J S Malpas; R T Oliver
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.